425 related articles for article (PubMed ID: 17609306)
1. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer.
Pilli T; Brianzoni E; Capoccetti F; Castagna MG; Fattori S; Poggiu A; Rossi G; Ferretti F; Guarino E; Burroni L; Vattimo A; Cipri C; Pacini F
J Clin Endocrinol Metab; 2007 Sep; 92(9):3542-6. PubMed ID: 17609306
[TBL] [Abstract][Full Text] [Related]
2. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.
Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A
J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.
Tresoldi AS; Sburlati LF; Rodari M; Schinkelshoek MS; Perrino M; De Leo S; Montefusco L; Colombo P; Arosio M; Lania AGA; Fugazzola L; Chiti A
J Endocrinol Invest; 2014 Aug; 37(8):709-714. PubMed ID: 24844565
[TBL] [Abstract][Full Text] [Related]
4. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
5. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
Mazzaferri EL; Kloos RT
J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
[TBL] [Abstract][Full Text] [Related]
7. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
8. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.
Pacini F; Ladenson PW; Schlumberger M; Driedger A; Luster M; Kloos RT; Sherman S; Haugen B; Corone C; Molinaro E; Elisei R; Ceccarelli C; Pinchera A; Wahl RL; Leboulleux S; Ricard M; Yoo J; Busaidy NL; Delpassand E; Hanscheid H; Felbinger R; Lassmann M; Reiners C
J Clin Endocrinol Metab; 2006 Mar; 91(3):926-32. PubMed ID: 16384850
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
10. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
11. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.
Pacini F; Molinaro E; Lippi F; Castagna MG; Agate L; Ceccarelli C; Taddei D; Elisei R; Capezzone M; Pinchera A
J Clin Endocrinol Metab; 2001 Dec; 86(12):5686-90. PubMed ID: 11739420
[TBL] [Abstract][Full Text] [Related]
12. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
[TBL] [Abstract][Full Text] [Related]
13. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma.
Pitoia F; Tamer EE; Schere DB; Passerieu M; Bruno OD; Niepomniszcze H
Medicina (B Aires); 2006; 66(2):125-30. PubMed ID: 16715760
[TBL] [Abstract][Full Text] [Related]
15. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
[TBL] [Abstract][Full Text] [Related]
16. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
17. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
Vrachimis A; Schober O; Riemann B
Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
[TBL] [Abstract][Full Text] [Related]
18. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.
Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O
J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
Ma C; Xie J; Liu W; Wang G; Zuo S; Wang X; Wu F
Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD008302. PubMed ID: 21069705
[TBL] [Abstract][Full Text] [Related]
20. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients.
Tala Jury HP; Castagna MG; Fioravanti C; Cipri C; Brianzoni E; Pacini F
J Clin Endocrinol Metab; 2010 Jan; 95(1):230-7. PubMed ID: 19858316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
